[Federal Register Volume 85, Number 38 (Wednesday, February 26, 2020)]
[Notices]
[Pages 11053-11054]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-03788]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Uniform Formulary Beneficiary Advisory Panel; Notice of Federal 
Advisory Committee Meeting

AGENCY: Under Secretary of Defense for Personnel and Readiness, 
Department of Defense (DoD).

ACTION: Notice of Federal Advisory Committee meeting.

-----------------------------------------------------------------------

SUMMARY: The DoD is publishing this notice to announce that the 
following Federal Advisory Committee meeting of the Uniform Formulary 
Beneficiary Advisory Panel (UFBAP) will take place.

DATES: Open to the public Wednesday, April 1, 2020, from 9:00 a.m. to 
12:00 p.m.

ADDRESSES: The address of the open meeting is the Naval Heritage Center 
Theater, 701 Pennsylvania Avenue NW, Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT:  Colonel Paul J. Hoerner, U.S. Air 
Force, 703-681-2890 (Voice), None (Facsimile), [email protected] (Email). Mailing address is 7700 Arlington 
Boulevard, Suite 5101, Falls Church, VA 22042-5101. Website: https://health.mil/bap. The most up-to-date changes to the meeting agenda can 
be found on the website.

SUPPLEMENTARY INFORMATION:  This meeting is being held under the 
provisions of the Federal Advisory Committee Act (FACA) of 1972 (5 
U.S.C., Appendix, as amended), the Government in the Sunshine Act of 
1976 (5 U.S.C. 552b, as amended), and 41 CFR 102-3.140 and 102-3.150.
    The UFBAP will review and comment on recommendations made to the 
Director of the Defense Health Agency, by the Pharmacy and Therapeutics 
Committee, regarding the Uniform Formulary.
    Purpose of the Meeting: The DoD is publishing this notice to 
announce that the following Federal Advisory Committee meeting of the 
UFBAP will take place.

Agenda: Wednesday, April 1, 2020, from 9:00 am to 12:00 pm
1. Sign-In
2. Welcome and Opening Remarks
3. Scheduled Therapeutic Class Reviews (Comments will follow each 
agenda item)
    a. Pain Agents--Non-Steroidal Anti-Inflammatory Drug (NSAID)
    b. Pain Agents--Topical Pain
4. Newly Approved Drugs Review
5. Pertinent Utilization Management Issues
6. UFBAP Discussions and Vote

    Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 
41 CFR 102-3.140 through 102-3.165, this meeting is open to the public, 
subject to the availability of space. Seating is limited and will be 
provided to the first 220 people. All persons must sign in legibly.
    Written Statements: Pursuant to 41 CFR 102-3.140, and section 
10(a)(3) of FACA, interested persons or organizations may submit 
written statements to the UFBAP about its mission and/or the agenda to 
be addressed in this public meeting. Written statements should be 
submitted to the UFBAP's Designated Federal Officer (DFO). The DFO's 
contact information can be found in the FOR FURTHER INFORMATION CONTACT 
section of this notice. Written comments or statements must be received 
by the UFBAP's DFO at least five (5) business days prior to the meeting 
so they may

[[Page 11054]]

be made available to the UFBAP for its consideration prior to the 
meeting. The DFO will review all submitted written statements and 
provide copies to all UFBAP members.

    Dated: February 20, 2020.
Aaron T. Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2020-03788 Filed 2-25-20; 8:45 am]
BILLING CODE 5001-06-P